| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Labit, B., et al.
(författare)
-
Progress in the development of the ITER baseline scenario in TCV
- 2024
-
Ingår i: Plasma Physics and Controlled Fusion. - 1361-6587 .- 0741-3335. ; 66:2
-
Tidskriftsartikel (refereegranskat)abstract
- Under the auspices of EUROfusion, the ITER baseline (IBL) scenario has been jointly investigated on AUG and TCV in the past years and this paper reports on the developments on TCV. Three ITER shapes, namely the JET, AUG and ITER IBL have been reproduced in TCV, illustrating that the higher the triangularity the larger the ELM perturbation and the more difficult it is to reach stationary states with q(95)< 3.6. It is found that the performance of TCV IBL is mainly limited by (neoclassical) tearing modes, in particular 2/1 modes which are triggered after a large ELM. It is demonstrated that the shorter the ELM period the larger beta(N) at the NTM onset. We show that these modes can be avoided with central X3 EC heating at relatively high q(95) and moderate beta(N). However, the lack of significant ECH at the high central densities obtained in TCV IBL scenario limits the duration of low q(95) cases to about four confinement times. During this time, density usually keeps peaking until (neoclassical) tearing modes are triggered. Nevertheless, the TCV IBL database covers the ITER target values (H-98y2 similar to 1, beta(N) similar to 1.8 at q(95 )similar to 3) and a slightly better confinement than requested for ITER is
|
|
| 5. |
- Landolfo, C., et al.
(författare)
-
Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors : retrospective validation on IOTA 5 multicenter cohort
- 2023
-
Ingår i: Ultrasound in Obstetrics and Gynecology. - : Wiley. - 0960-7692 .- 1469-0705. ; 61:2, s. 231-242
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: Previous work suggested that the ultrasound-based benign Simple Descriptors can reliably exclude malignancy in a large proportion of women presenting with an adnexal mass. We aim to validate a modified version of the Benign Simple Descriptors (BD), and we introduce a two-step strategy to estimate the risk of malignancy: if the BDs do not apply, the ADNEX model is used to estimate the risk of malignancy. Methods: This is a retrospective analysis using the data from the 2-year interim analysis of the IOTA5 study, in which consecutive patients with at least one adnexal mass were recruited irrespective of subsequent management (conservative or surgery). The main outcome was classification of tumors as benign or malignant, based on histology or on clinical and ultrasound information during one year of follow-up. Multiple imputation was used when outcome based on follow-up was uncertain according to predefined criteria. Results: 8519 patients were recruited at 36 centers between 2012 and 2015. We included all masses that were not already in follow-up at recruitment from 17 centers with good quality surgical and follow-up data, leaving 4905 patients for statistical analysis. 3441 (70%) tumors were benign, 978 (20%) malignant, and 486 (10%) uncertain. The BDs were applicable in 1798/4905 (37%) tumors, and 1786 (99.3%) of these were benign. The two-step strategy based on ADNEX without CA125 had an area under the receiver operating characteristic curve (AUC) of 0.94 (95% CI, 0.91-0.95). The risk of malignancy was slightly underestimated, but calibration varied between centers. A sensitivity analysis in which we expanded the definition of uncertain outcome resulted in 1419 (29%) tumors with uncertain outcome and an AUC of the two-step strategy without CA125 of 0.93 (95% CI, 0.91-0.95). Conclusion: A large proportion of adnexal masses can be classified as benign by the BDs. For the remaining masses the ADNEX model can be used to estimate the risk of malignancy. This two-step strategy is convenient for clinical use.
|
|
| 6. |
|
|
| 7. |
- Landolfo, C., et al.
(författare)
-
Differences in ultrasound features of papillations in unilocular-solid adnexal cysts : a retrospective international multicenter study
- 2018
-
Ingår i: Ultrasound in Obstetrics and Gynecology. - : Wiley. - 0960-7692. ; 52:2, s. 269-278
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives: To identify ultrasound features of papillations or of the cyst wall that can discriminate between benign and malignant unilocular-solid cysts with papillations but no other solid components. Methods: From the International Ovarian Tumor Analysis (IOTA) database derived from seven ultrasound centers, we identified patients with an adnexal lesion described at ultrasonography as unilocular-solid with papillations but no other solid components. All patients had undergone transvaginal ultrasound between 1999 and 2007 or 2009 and 2012, by an experienced examiner following the IOTA research protocol. Information on four ultrasound features of papillations had been collected prospectively. Information on a further seven ultrasound features was collected retrospectively from electronic or paper ultrasound images of good quality. The histological diagnosis of the surgically removed adnexal lesion was considered the gold standard. Results: Of 204 masses included, 131 (64.2%) were benign, 42 (20.6%) were borderline tumors, 30 (14.7%) were primary invasive tumors and one (0.5%) was a metastasis. Multivariate logistic regression analysis showed the following ultrasound features to be associated independently with malignancy: height of the largest papillation, presence of blood flow in papillations, papillation confluence or dissemination, and shadows behind papillations. Shadows decreased the odds of malignancy, while the other features increased them. Conclusion: We have identified ultrasound features that can help to discriminate between benign and malignant unilocular-solid cysts with papillations but no other solid components. Our results need to be confirmed in prospective studies.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- El Bairi, Khalid, et al.
(författare)
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
- 2021
-
Ingår i: npj Breast Cancer. - : Springer Science and Business Media LLC. - 2374-4677. ; 7:1
-
Forskningsöversikt (refereegranskat)abstract
- The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.
|
|
